Invesco is in a sustained uptrend over the past year, with the stock price up 66.55% from a year ago, significantly outperforming the S&P 500's 20.63% gain. The current price of $28.98 sits at 97.2% of its 52-week range ($16.49–$29.82), indicating the stock is trading near its highs, which suggests strong momentum but also potential overextension near resistance. The 52-week low of $16.49 provides a clear support level, while the high of $29.82 is the immediate resistance. With a beta of 1.597, Invesco is about 60% more volatile than the market, amplifying both upside and downside moves. Short-term momentum is robust: the 1-month price change is +5.54% and the 3-month change is +22.90%, both outpacing the S&P 500's respective gains of 4.07% and 11.11%. This acceleration in short-term momentum relative to the longer-term trend (1-year +66.55%) suggests the stock is gaining near-term strength, though the 6-month change of +1.44% indicates a period of consolidation earlier in the period. The relative strength versus the S&P 500 over 1 month (1.47) and 3 months (11.79) confirms recent outperformance, while the 6-month relative strength is slightly negative (-7.33), hinting at a potential divergence that could signal a temporary pullback if momentum fades. The 52-week high of $29.82 is a key resistance level; a breakout above that would signal a continuation of the uptrend and likely attract further buying. Conversely, the 52-week low of $16.49 is a major support, and a breakdown below that would negate the long-term uptrend. Given the beta of 1.597, the stock is more volatile than the market, meaning any market downturn could lead to sharper declines, and position sizing should account for this higher risk.

Invesco's revenue trajectory is growing, with the most recent quarterly revenue (Q4 2025) at $1.692 billion, up 6.21% year-over-year from $1.593 billion in Q4 2024. Over the trailing twelve months, revenue has been steadily increasing: Q1 2025 $1.529B, Q2 $1.516B, Q3 $1.640B, Q4 $1.692B, indicating a consistent upward trend. Revenue segments show that investment advice fees ($1.229 billion) are the primary driver, accounting for 72.6% of total revenue, while distribution and shareholder service fees ($383 million) contribute 22.6%. The growth is broad-based, but the reliance on asset-based fees means market performance directly impacts revenue. The 6.2% YoY growth is positive but modest, suggesting the investment case hinges on margin expansion and cost control rather than explosive top-line growth. Profitability is mixed: Invesco reported a net loss of -$1.061 billion in Q4 2025, driven by a large non-cash impairment charge (other expenses of $2.418 billion), which swung net income from positive in prior quarters. Excluding this charge, operating income was -$1.458 billion, but the underlying business remains profitable on an adjusted basis. Gross margin in Q4 2025 was 66.96%, up from 37.83% in Q4 2024, but this reflects a change in revenue mix (higher-margin investment advice fees). The operating margin was -86.18% in Q4 2025 due to the impairment, but in Q3 2025 it was a healthy 16.51%. The net margin for the TTM is -4.42%, but excluding the impairment, it would be positive. The trajectory toward normalized profitability is key: the company needs to demonstrate that the impairment is a one-time event and that margins can expand toward historical levels. Invesco's balance sheet is moderately leveraged with a debt-to-equity ratio of 0.83, which is manageable but not conservative. Free cash flow (TTM) is strong at $1.560 billion, providing ample coverage for dividends and debt service. The current ratio of 43.01 is extremely high, indicating ample liquidity, though this is partly due to the nature of the asset management business (cash held for fund operations). Return on equity is negative (-2.30%) due to the impairment loss, but normalized ROE is likely in the mid-single digits. The company generated $1.56 billion in free cash flow over the TTM, representing a free cash flow yield of about 13.2% at the current market cap, which is attractive and supports the dividend (yield 4.91%). Overall, the balance sheet is healthy, with strong cash generation offsetting moderate debt levels.